NasdaqGS:NUVLBiotechs
Does Nuvalent (NUVL) Have the Pipeline Depth to Justify Its Global Expansion Ambitions?
Nuvalent, Inc. recently announced that the U.S. FDA accepted New Drug Applications for its investigational lung cancer therapies neladalkib and zidesamtinib, granting Priority Review to neladalkib and setting target action dates of September 18 and November 27, 2026, respectively.
Together with the appointment of Georg Pirmin Meyer, M.D., as Chief International Officer, these milestones highlight Nuvalent’s push to build a global commercial footprint around its late-stage oncology...